<div id="readability-page-1"><div id="article-body-3236600"><div><p>Refinitiv StreetEvents Event Transcript<br/>E D I T E D   V E R S I O N</p><p>ORIC.OQ - Oric Pharmaceuticals Inc<br/>Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call<br/>Dec 07, 2025 / 01:00AM GMT </p><p>=====================<br/>Presentation<br/>--------------------------------------------------------------------------------<br/>Unidentified_1   [1]<br/>--------------------------------------------------------------------------------<br/> Good day and thank you for standing by. Welcome to the Aic Enozertiib program update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising that your hand has been raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Dominic Piccitelli, Chief Financial Officer. Please go ahead.</p><p>---------------------------------------------------------------</p></div><p><em>This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to <span>[email protected]</span>.</em></p></div></div>

ORIC

<p>Oric Pharmaceuticals Inc held a program update call for Enozertinib (ORIC-114) on December 7, 2025. The call included a presentation by Dominic Piccitelli, CFO, followed by a Q&A session. The event was recorded and aimed to provide timely market reporting using GuruFocus financial data.</p>

Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript